Literature DB >> 18025760

Reduced carnitine level causes death from hypoglycemia: possible involvement of suppression of hypothalamic orexin expression during weaning period.

Masamichi Kuwajima1, Hiroaki Fujihara, Hiroyoshi Sei, Asako Umehara, Masako Sei, Tomi T Tsuda, Akiko Sukeno, Tatsuya Okamoto, Akiko Inubushi, Yoichi Ueta, Toshio Doi, Hiroshi Kido.   

Abstract

The mechanism of onset of hypoglycemia in patients with carnitine deficiency has yet to be determined. Using mice with systemic carnitine deficiency (JVS mice), we examined this mechanism, focusing on the weaning period (days 14-28 postpartum). For normal mice, the survival rate was 100%, and no hypoglycemia was observed at all. Gastric lactose began to decrease on day 17, and cellulose increased sharply in amount thereafter. For JVS mice, the survival rate was 77% on day 14 and 28% on day 28. From day 21 on, hypoglycemia was noted. Gastric lactose had disappeared almost completely by day 17, and cellulose was almost undetectable from days 14 to 28. Expression of orexin mRNA in the hypothalamus did not differ between JVS and normal mice on day 14, but was suppressed in JVS mice on days 21 and 28. When JVS mice were fed a carnitine-rich diet, suppression of expression of orexin mRNA in hypothalamus was eliminated, and on day 28 lactose and cellulose were detected in the stomach without hypoglycemia. In conclusion, the suppression of the expression of orexin in the hypothalamus during the weaning period may be involved in the marked anorexia in JVS mice, which eventually leads to death from hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025760     DOI: 10.1507/endocrj.k07-044

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

Review 1.  Genome-wide association studies of sleep disorders.

Authors:  David M Raizen; Mark N Wu
Journal:  Chest       Date:  2011-02       Impact factor: 9.410

2.  Abnormally low serum acylcarnitine levels in narcolepsy patients.

Authors:  Taku Miyagawa; Hiroko Miyadera; Susumu Tanaka; Minae Kawashima; Mihoko Shimada; Yutaka Honda; Katsushi Tokunaga; Makoto Honda
Journal:  Sleep       Date:  2011-03-01       Impact factor: 5.849

3.  Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.

Authors:  Edgars Liepinsh; Reinis Vilskersts; Liga Zvejniece; Baiba Svalbe; Elina Skapare; Janis Kuka; Helena Cirule; Solveiga Grinberga; Ivars Kalvinsh; Maija Dambrova
Journal:  Br J Pharmacol       Date:  2009-07-07       Impact factor: 8.739

4.  L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.

Authors:  Hisashi Ishikawa; Akinobu Takaki; Ryuichiro Tsuzaki; Tetsuya Yasunaka; Kazuko Koike; Yasuyuki Shimomura; Hiroyuki Seki; Hiroshi Matsushita; Yasuhiro Miyake; Fusao Ikeda; Hidenori Shiraha; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

5.  Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (essential hypersomnia).

Authors:  Taku Miyagawa; Makoto Honda; Minae Kawashima; Mihoko Shimada; Susumu Tanaka; Yutaka Honda; Katsushi Tokunaga
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

6.  Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial.

Authors:  Taku Miyagawa; Hiromi Kawamura; Mariko Obuchi; Asuka Ikesaki; Akiko Ozaki; Katsushi Tokunaga; Yuichi Inoue; Makoto Honda
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

Review 7.  Impact of L-carnitine in narcolepsy treatment: a systematic review on the effectiveness and safety.

Authors:  Cristina Salles; Maria Clara Freitas; Miguel Meira E Cruz
Journal:  Sleep Sci       Date:  2022 Jan-Mar
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.